Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filgrastim + stem cell factor
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Filgrastim + stem cell factor is a combination of two recombinant protein drugs used to enhance the mobilization of hematopoietic progenitor (stem) cells into the peripheral blood, primarily for collection prior to autologous or allogeneic transplantation. Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursors and increases neutrophil counts. Stem cell factor (SCF), also known as c-kit ligand, acts synergistically with G-CSF to further increase the yield of CD34+ hematopoietic progenitor cells in peripheral blood. The combination has been shown in clinical studies to significantly increase CD34+ cell yields and reduce the number of leukapheresis sessions required compared to filgrastim alone[1][3][5]. This regimen is mainly investigated in patients undergoing high-dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation, such as those with multiple myeloma or high-risk breast cancer[1][3].
- Brand names
- Ancestim + NeupogenStemgen + Neupogen
- Other names
- G-CSF + SCFgranulocyte colony-stimulating factor + stem cell factor
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on filgrastim + stem cell factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filgrastim + stem cell factor.